Canada
MicroSintesis Inc. is a pioneering biotechnology firm headquartered in Canada, founded in 2011. The company aims to transform both human and animal healthcare by fully harnessing the potential of the microbiome, ultimately altering how diseases are combated. Their slogan, "Harnessing microbiome's full potential to change the way we fight diseases," encapsulates this mission.
Unlike conventional probiotics, MicroSintesis Inc. advances the science of microbiome communication, focusing on quorum sensing to prevent dysbiosis-related illnesses. The company's unique patented metabolite stands at the core of these innovations, emphasizing a science-based approach to address major healthcare challenges like antibiotic resistance.
Their most recent funding event was a $16.40M Venture Round led by Northern Private Capital (NPC) on June 27, 2019. This investment supports the development of alternative solutions to current antibiotic treatments, reflecting the firm’s commitment to leading microbiome research for enhanced global health outcomes.
